Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$576 Mln
Revenue (TTM)
$144 Mln
Net Profit (TTM)
$0 Mln
ROE
-0 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
1
Industry P/E
--
EV/EBITDA
7.2
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-0.2
Face value
--
Shares outstanding
121,550,000
CFO
€42.62 Mln
EBITDA
€-234.20 Mln
Net Profit
€-447.07 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Immatics NV (IMTX)
| -24.1 | 26.8 | 13.2 | -50.7 | -6.5 | -13.1 | -- |
|
BSE Sensex*
| 4.3 | 3.9 | 7.7 | 10.3 | 14.5 | 21.5 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
|---|---|---|---|
|
Immatics NV (IMTX)
| 20.9 | -35.2 | 24.6 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies... with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany. Address: Paul-Ehrlich-Strasse 15, Tübingen, Germany, 72076 Read more
CEO, MD, Member of Management Board & Executive Director
Dr. Harpreet Singh Ph.D.
CEO, MD, Member of Management Board & Executive Director
Dr. Harpreet Singh Ph.D.
Headquarters
Tübingen
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Immatics NV (IMTX) stood at $ 697 Mln as on 31-Mar-25
The share price of Immatics NV (IMTX) is $5.40 (NASDAQ) as of 20-May-2025 16:00 EDT. Immatics NV (IMTX) has given a return of -6.52% in the last 3 years.
Immatics NV (IMTX) has a market capitalisation of $ 576 Mln as on 19-May-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Immatics NV (IMTX) is 0.96 times as on 19-May-2025, a 66% discount to its peers’ median range of 2.83 times.
Since, TTM earnings of Immatics NV (IMTX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Immatics NV (IMTX) and enter the required number of quantities and click on buy to purchase the shares of Immatics NV (IMTX).
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany. Address: Paul-Ehrlich-Strasse 15, Tübingen, Germany, 72076
The CEO & director of Dr. Harpreet Singh Ph.D.. is Immatics NV (IMTX), and CFO & Sr. VP is Dr. Harpreet Singh Ph.D..
There is no promoter pledging in Immatics NV (IMTX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| Immatics NV (IMTX) | Ratios |
|---|---|
|
Return on equity(%)
|
-4.7
|
|
Operating margin(%)
|
16.48
|
|
Net Margin(%)
|
-14.97
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Immatics NV (IMTX) was $0 Mln.
$0.11
(
